Mar 30, 2016 - Ms. LIU Xuezi, age 39, is a Non-executive Director of our Company. ... of University of San Francisco, ma
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
LANSEN PHARMACEUTICAL HOLDINGS LIMITED 朗生醫藥控股有限公司 (incorporated in the Cayman Islands with limited liability) (Stock code: 503)
CHANGE OF NON-EXECUTIVE DIRECTOR, EXECUTIVE DIRECTOR, AUTHORIZED REPRESENTATIVE AND MEMBER OF EXECUTIVE COMMITTEE RESIGNATION OF NON-EXECUTIVE DIRECTOR The board (the “Board”) of directors (the “Directors”) of Lansen Pharmaceutical Holdings Limited (the “Company”) announces that due to other work commitments, Ms. Yip Pui Ling, Rebecca and Ms. Tao Fang Fang have resigned as Non-executive Directors of the Company of the Company with effect from 30 March 2016. Upon her resignation, Ms. Yip will cease to be a member of the Audit Committee of the Company and one of the authorized representatives of the Company (for the purpose of Rule 3.05 of the Rules Governing the Listing of Securities (the “Listing Rules”) on The Stock Exchange of Hong Kong Limited (the ‘‘Stock Exchange’’)). Ms. Yip and Ms. Tao confirmed that they have no disagreement with the Board and there is no matter relating to their resignation as Non-executive Directors that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange. The Board wishes to express its appreciation for Ms. Yip’s and Ms. Tao’s contribution during their term of office.
APPOINTMENT OF NON-EXECUTIVE DIRECTOR The Company is pleased to announce that Ms. Liu Xuezi has been appointed as a Nonexecutive Director with effect from 30 March 2016. Ms. LIU Xuezi, age 39, is a Non-executive Director of our Company. Ms. Liu joined Cathay International Holdings Limited (“Cathay”) in 2002 and has been working in the corporate development department and asset management department. She is currently the vice president and co-head of asset management of Cathay and she is the director of various subsidiaries of the Group. Ms. Liu has over 14 years of experience in mergers and acquisitions and asset management. Before joining Cathay, Ms. Liu was the head of the 1
Asia-Pacific region of a US network infrastructure company, and was responsible for the start-up and expansion of the company’s business in Asia. Ms. Liu graduated from the School of Economics of University of San Francisco, majoring in business administration, in 1999. Save as disclosed above, as at the date of this announcement, Ms. Liu does not hold any other position in the Company or its subsidiaries. Ms. Liu does not have any relationship with any directors, members of senior management, or substantial or controlling shareholders of the Company (as defined by the Listing Rules) and she has no interest in the securities of the Company within the meaning of Part XV of the Securities and Future Ordinance (Cap. 571 of the laws of Hong Kong). She has not held any directorships in listed public companies in the last three years. Ms. Liu has entered into a letter of appointment with the Company for a term of three years commencing on 30 March 2016. Ms. Liu is not entitled to receive any emolument or Director’s fee from the Company.
APPOINTMENT OF EXECUTIVE EXECUTIVE COMMITTEE
DIRECTOR
AND
MEMBER
OF
The Board announces that Mr. Hou Song (“Mr. Hou”) will be appointed as the Executive Director and authorized representative of the Company (for the purpose of Rules 3.05 of the Listing Rules) and a member of the Executive Committee with effect from 30 March 2016. Mr. Hou Song, age 40, is the Executive Director and the chief financial officer of the Company. Mr. Hou joined the Group in September 2015. Mr. Hou has over 15 years of experience in finance, accounting and corporate management in Hong Kong and mainland China. Mr. Hou has many years of experience in financial management in large pharmaceutical companies. He had worked as deputy finance officer of the Company from 2007 to 2008. Mr. Hou graduated from Sun Yat-sen University with a bachelor of economics degree in accounting in 2000 and, in 2015, obtained a MBA degree in the MBA Program in Finance offered by The Chinese University of Hong Kong in collaboration with Tsinghua University. Mr. Hou is a qualified accountant in the People’s Republic of China. Save as disclosed above, as at the date of this announcement, Mr. Hou does not hold any other position in the Company or its subsidiaries. Mr. Hou does not have any relationship with any directors, members of senior management, or substantial or controlling shareholders of the Company (as defined by the Listing Rules) and he has no interest in the securities of the Company within the meaning of Part XV of the Securities and Future Ordinance (Cap. 571 of the laws of Hong Kong). He has not held any directorships in listed public companies in the last three years. Pursuant to the service contract dated 30 March 2016 between Mr. Hou and the Company, Mr. Hou is entitled to remuneration for his current employment in the Group, to be determined by the Board with reference to his experience, performance and duties as well as the prevailing market conditions. Mr. Hou will not be entitled to any extra remuneration under the service contract. The service contract may be terminated by either Mr. Hou or the Company by giving to the other party not less than three months’ written notice without payment of compensation (other than statutory compensation). Save as disclosed above, there is no other information that is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules or any other matters that 2
need to be brought to the attention of the shareholders of the Company in connection with the appointment of Ms. Liu and Mr. Hou. The Board would like to take this opportunity to welcome Ms. Liu and Mr. Hou to join the Board.
By order of the Board Lansen Pharmaceutical Holdings Limited Stephen Burnau Hunt Chairman Hong Kong, 30 March 2016 As at the date of this announcement, the executive Director is Mr. Liu Bang Min; the nonexecutive Directors are Mr. Stephen Burnau Hunt, Mr. Lee Jin Yi, Mr. Tang Jun, Ms. Tao Fang Fang and Ms. Yip Pui Ling, Rebecca; the independent non-executive Directors are Mr. Chan Kee Huen, Michael, Mr. Tang Chiu Ping, Raymond and Mr. Fritz Heinrich Horlacher.
3
